required intensified treatment schemes (of up to 10 weeks) for clearance. The 2 tumors that did not clear responded partially and were also the 2 largest ones (diameter 40 and 60 mm). Of the 14 cleared tumors, 2 relapsed during followup; 1 cleared with immunocryosurgery. At the last examination during follow-up, 13 out of 16 (81%) patients were in sustained clinical remission. Conclusions: For most pBCC, immunocryosurgery is a feasible and efficacious alternative to surgical excision.
Introduction
Periocular basal cell carcinomas (pBCC) represent 90% of eyelid malignancies [1] and, due to their localization, can endanger structures that are important for the proper function of the eye. Furthermore, inherent to all therapeutic approaches for tumors of this localization, including surgical treatment [2] and radiotherapy, is the risk of side effects from ocular adnexa (e.g. development of ectropion or damage to the lacrimal apparatus). In order to constrain this hazard, reduction of the tumor burden with employment of topical imiquimod [3] or the novel hedgehog inhibitor vismodegib [4] prior to surgery is proposed.
Immunocryosurgery was pioneered in our department [5, 6] and entails the combination of relatively mild cryosurgery with continuous imiquimod application. Elaborate protocols for this combination modality are now offered within the framework of approved clinical trials to patients with BCC attending the dedicated dermato-oncology clinic of our department, as a therapeutic alternative to surgery or when the latter is considered inappropriate. Meanwhile, we have demonstrated in 2 trials the significance of the timing of cryosurgery [7] and the high efficacy of this combinational modality for tumors with a maximal diameter ≤ 20 mm [8] . Furthermore, a previous pilot study claimed promising feasibility and efficacy of immunocryosurgery in 3 cases that were difficult to treat with conventional pBCC methods [9] .
The aim of the present retrospective study was to evaluate the feasibility and efficacy of immunocryosurgery in a larger series of pBCC treated during a 7-year period.
Patients and Methods
Institutional Review Committee permission was granted and files of patients with BCC treated with immunocryosurgery between 1/1/2008 and 31/12/2014 were reviewed for periocular tumors, i.e. either BCC located within 1 cm of the eyelid margins, irrespective of their size, or tumors in which a conventional surgical therapeutic approach with appropriate excision margins would impact the functional integrity of the eyelids, with possible short or long-term sequelae for the ocular surface. Tumor diagnosis and histopathologic characteristics were assessed via a punch biopsy [10] . As a standard of care, prior to the initiation of immunocryosurgery the patients were screened by an ophthalmologist to exclude active eye diseases which might constitute a contraindication for the planned treatment modality (primarily eye conditions with severe ocular surface inflammation, e.g. ocular cicatricial pemphigoid, or scleritis and uveitis). The aggregate risk factors for relapse after treatment according to the current guidelines were determined for each pBCC [11] . Notably, the periocular localization of all of the tumors treated herein constitutes a risk factor for relapse after treatment [11] .
Immunocryosurgery is a minimally invasive combination modality that is performed in 5-week treatment cycles. Each treatment cycle consists of daily application of an adequate quantity (20-30%) is subsequently inserted for optimal ocular protection by covering the ocular surface. If pertinent, patients are asked to close their eyes and additional cryoprotection is offered with a sterile wooden tongue depressor covered with a sterile gauge. For tumors located in the medial canthus, the convex edge of the wooden tongue depressor covered with the gauge is gently pressed between the tumor site and the medial canthus of the adjacent eye to create a physical thermal barrier. For tumors involving the lower eyelid, this is retracted and gently rolled out to expose the tumor, and the long straight edge of the wooden depressor enveloped in gauge impregnated with ophthalmic 0.3% tobramycin ointment is used to maximize eye protection from thermal trauma. Open spray cryosurgery is applied with the nozzle approximately 1 cm away from the tumor. Freezing time begins once the target tissue volume is completely frozen and the ice ball state of the tumor area continues for 15 s. During spraying, care is taken to ensure that the liquid nitrogen scatters away from the eyes. Subsequently, the frozen tissues are allowed to thaw spontaneously. As a rule, the thawing times with this procedure are short and thus they are not routinely registered. Also, as the tongue depressor has some degree of freezing, too, it is not removed until the thawing is complete. The second cycle is repeated likewise. For cryosurgery of tumors with a surface area >1.5 cm 2 , the treatment area is divided into slightly overlapping 1-cm 2 segments. Tobramycin ointment is applied after the end of the procedure. Imiquimod cream is applied by the patient at home as on previous nights. The technical details of cryosurgery within immunocryosurgery have been also presented elsewhere [6, 12] . A principal criterion for treatment duration is tumor size, as BCC with diameters >20 mm require intensified treatment schemes with repeated cryosurgery sessions [6] . For these tumors, therapy is essentially individualized, with extended imiquimod application periods (up to 10 weeks) during which cryosurgery sessions are performed every 2 weeks, starting on day 14 of treatment. Alternatively, conventional 5-week immunocryosurgery therapy cycles can be repeated, separated by treatment breaks. When the patient cannot tolerate therapy due to escalation of (local) adverse events, the treatment protocol is appropriately adapted. For these cases, we recommend imiquimod 'contact treatment' in which the cream is removed by washing after 15-30 min of application [9] .
Results
Immunocryosurgery was offered to 19 patients, 16 of whom consented to treatment (6 males and 10 females, average age 74.9 years, median tumor diameter 15 mm, range 5-60 mm, 1 pBCC per patient). Table 1 shows the core demographic data and tumor characteristics of the 16 patients (including updated data of 3 patients already presented in the past) [9] , and figure 1 a and b exemplifies a typical treatment outcome (patient No. 5). Six of the 16 tumors (37.5%) were relapses after surgery. Ten pBCC had 2 risk factors for recurrence, 5 had 3, and 1 had 4 ( [9] . L = Left; R = right; F = female; M = male; NA = not available. during follow-up. One relapse (No. 12) responded to a repeat immunocryosurgery treatment cycle and remained relapse free for 12 months. The other pBCC (patient No. 9) relapsed at 6 months of follow-up; the patient denied any additional interventions and was subsequently lost to follow-up. Taken together, at the last examination during follow-up, 13 out of 16 (81%) patients (irrespectively of tumor size) were clinically tumor free, i.e. in sustained clinical remission. It is worth noting that for pBCC <40 mm in maximal diameter the overall therapeutic efficacy of immunocryosurgery was 92.8% (13 out of 14 tumors).
During treatment, all patients developed erythema and mild swelling of the conjunctiva along with a foreignbody sensation (probably a type of chemical-immunemediated conjunctivitis), which was intensified for the first 2-3 days after the cryosurgery session. This was accompanied by eyelid edema, which gradually subsided after the end of treatment. All adverse events, though disturbing, resolved without a trace 2 weeks after the end of treatment. One patient (No. 6) with a metatypical pBCC that had relapsed after surgery developed a hypertrophic scar following immunocryosurgery that gradually decreased in size over time ( fig. 1 c-e) . Taken together, the adverse effects were adequately tolerated with appropriate physician's support and all patients completed the treatment scheme.
Discussion
Surgery is currently the suggested treatment for BCC, including tumors of periocular localization [13, 14] . However, in order to maximize the preservation of ocular adnexal structures, surgical safety margins for periocular skin tumors tend to be selected as narrowly as possible, resulting in an increased rate of non-R0 pBCC resections and increased relapse hazards [2] . Despite these distinct treatment needs, randomized controlled trials evaluating Mohs' micrographic surgery versus standard surgical excision for this tumor localization are not found in the literature [15] .
Investigations yielding results of topical imiquimod application to treat periocular tumors and in particular pBCC are only sporadically reported. The largest series to date [16] recorded treatment outcomes in 19 patients with primary neoplasms of diameters <30 mm. Imiquimod was applied 5 days/week (once daily) and rather prolonged treatment periods (8-16 weeks) were required in order to achieve a satisfactory tumor clearance rate (16/19 tumors, 84.2% at the 3-year follow-up) . Likewise, in another study a sustained complete response was accomplished in 15 patients with rather small pBCC ( ≤ 13 mm in largest diameter) with imiquimod 5 days/week (once daily) for 6 weeks [17] . Compared to data in the literature [compiled recently in a paper by de Macedo et al. 16 ], our present combined approach is characterized by an equivalent efficacy rate (overall 87.5%, irrespectively of tumor size) with generally shorter (5-10, in most cases 5, treatment weeks), but more intense, treatment cycles (including synergistic combination with rather mild cryosurgery sessions during ongoing imiquimod application) [12] . As anticipated, this augmented treatment scheme is accompanied by a burden of topical, particularly ocular, adverse events that may cause some degree of discomfort during treatment. Thus, a detailed discussion with the patient regarding the treatment procedure and the expected self-limiting adverse events improves confidence and ensures compliance. This is further secured by unrestricted access of the patient to the physician during treatment [18, 19] . It is worth noting that contact of imiquimod with the ocular surface is generally safe and the substance has been successfully applied directly on conjunctival actinic keratoses for their treatment [20] . On the other hand, in the past decades cryosurgery has been extensively employed to treat pBCC and it has even been proposed as a tissue-sparing, first-line therapy for selected, mostly smaller (<1 cm in maximal diameter) [20] [21] [22] [23] or well-circumscribed pBCC [24] . Finally, with immunocryosurgery healing is generally excellent ( fig. 1 a, b) . One patient ( fig. 1 c-e) developed a hypertrophic scar that gradually subsided with time. This is a rare self-limiting adverse event that we have occasionally observed, and in other anatomic localizations with immunocryosurgery, especially when BCC recurrences after surgery are treated with this approach. Notably, physicians should be alerted not to confuse this tissue reaction with tumor relapses.
In conclusion, the present case series demonstrates that immunocryosurgery is a feasible and efficacious minimally invasive combination modality for pBCC. Thus it could be a convenient therapeutic alternative, particularly in cases where conventional surgery or Mohs' micrographic surgery are not available due to local infrastructure restrictions or are not suitable due to the characteristics of the tumor or the general condition of the patient.
